Eric Shiozaki

Eric is a Partner at DCVC Bio, a life science venture capital firm. Previously, he was a Partner at Novo Ventures where he established and managed the firm’s public equities strategy focused on smidcap and late-stage private companies in biotech and medtech. Earlier in his career Eric was a Director at Apposite Capital and an Associate at Burrill & Company. Having initially trained as a structural biologist, he was a Leukemia & Lymphoma Society Post-Doctoral Fellow. Eric received a B.A. in Biophysics from Johns Hopkins University and a Ph.D. in Molecular Biology from Princeton University.